Modeling ductal carcinoma in situ

A HER2-Notch3 collaboration enables luminal filling

C. R. Pradeep, W. J. Köstler, M. Lauriola, R. Z. Granit, F. Zhang, J. Jacob-Hirsch, G. Rechavi, H. B. Nair, B. T. Hennessy, A. M. Gonzalez-Angulo, R. R. Tekmal, I. Ben-Porath, Gordon Mills, E. Domany, Y. Yarden

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

Original languageEnglish (US)
Pages (from-to)907-917
Number of pages11
JournalOncogene
Volume31
Issue number7
DOIs
StatePublished - Feb 16 2012
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Up-Regulation
Apoptosis
Breast Neoplasms
Genetically Modified Animals
Cyclin D1
Oncogenes
Extracellular Matrix
Intercellular Signaling Peptides and Proteins
Breast
Epithelial Cells
Phenotype
Survival
Pharmaceutical Preparations
Neoplasms

Keywords

  • breast cancer
  • DCIS
  • growth factor
  • receptor tyrosine kinase
  • signal transduction
  • spheroids

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Pradeep, C. R., Köstler, W. J., Lauriola, M., Granit, R. Z., Zhang, F., Jacob-Hirsch, J., ... Yarden, Y. (2012). Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling. Oncogene, 31(7), 907-917. https://doi.org/10.1038/onc.2011.279

Modeling ductal carcinoma in situ : A HER2-Notch3 collaboration enables luminal filling. / Pradeep, C. R.; Köstler, W. J.; Lauriola, M.; Granit, R. Z.; Zhang, F.; Jacob-Hirsch, J.; Rechavi, G.; Nair, H. B.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Tekmal, R. R.; Ben-Porath, I.; Mills, Gordon; Domany, E.; Yarden, Y.

In: Oncogene, Vol. 31, No. 7, 16.02.2012, p. 907-917.

Research output: Contribution to journalArticle

Pradeep, CR, Köstler, WJ, Lauriola, M, Granit, RZ, Zhang, F, Jacob-Hirsch, J, Rechavi, G, Nair, HB, Hennessy, BT, Gonzalez-Angulo, AM, Tekmal, RR, Ben-Porath, I, Mills, G, Domany, E & Yarden, Y 2012, 'Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling', Oncogene, vol. 31, no. 7, pp. 907-917. https://doi.org/10.1038/onc.2011.279
Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J et al. Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling. Oncogene. 2012 Feb 16;31(7):907-917. https://doi.org/10.1038/onc.2011.279
Pradeep, C. R. ; Köstler, W. J. ; Lauriola, M. ; Granit, R. Z. ; Zhang, F. ; Jacob-Hirsch, J. ; Rechavi, G. ; Nair, H. B. ; Hennessy, B. T. ; Gonzalez-Angulo, A. M. ; Tekmal, R. R. ; Ben-Porath, I. ; Mills, Gordon ; Domany, E. ; Yarden, Y. / Modeling ductal carcinoma in situ : A HER2-Notch3 collaboration enables luminal filling. In: Oncogene. 2012 ; Vol. 31, No. 7. pp. 907-917.
@article{bf31509571f34ceca731b26040f5ff3a,
title = "Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling",
abstract = "A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.",
keywords = "breast cancer, DCIS, growth factor, receptor tyrosine kinase, signal transduction, spheroids",
author = "Pradeep, {C. R.} and K{\"o}stler, {W. J.} and M. Lauriola and Granit, {R. Z.} and F. Zhang and J. Jacob-Hirsch and G. Rechavi and Nair, {H. B.} and Hennessy, {B. T.} and Gonzalez-Angulo, {A. M.} and Tekmal, {R. R.} and I. Ben-Porath and Gordon Mills and E. Domany and Y. Yarden",
year = "2012",
month = "2",
day = "16",
doi = "10.1038/onc.2011.279",
language = "English (US)",
volume = "31",
pages = "907--917",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Modeling ductal carcinoma in situ

T2 - A HER2-Notch3 collaboration enables luminal filling

AU - Pradeep, C. R.

AU - Köstler, W. J.

AU - Lauriola, M.

AU - Granit, R. Z.

AU - Zhang, F.

AU - Jacob-Hirsch, J.

AU - Rechavi, G.

AU - Nair, H. B.

AU - Hennessy, B. T.

AU - Gonzalez-Angulo, A. M.

AU - Tekmal, R. R.

AU - Ben-Porath, I.

AU - Mills, Gordon

AU - Domany, E.

AU - Yarden, Y.

PY - 2012/2/16

Y1 - 2012/2/16

N2 - A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

AB - A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

KW - breast cancer

KW - DCIS

KW - growth factor

KW - receptor tyrosine kinase

KW - signal transduction

KW - spheroids

UR - http://www.scopus.com/inward/record.url?scp=84857112420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857112420&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.279

DO - 10.1038/onc.2011.279

M3 - Article

VL - 31

SP - 907

EP - 917

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -